View Item 

Show simple item record

Experience with Community‐Based Amphotericin B Infusion Therapy
dc.contributor.authorMalani, Preeti N.en_US
dc.contributor.authorDePestel, Daryl D.en_US
dc.contributor.authorRiddell, Jamesen_US
dc.contributor.authorBickley, Susanen_US
dc.contributor.authorKlein, Lisa R.en_US
dc.contributor.authorKauffman, Carol A.en_US
dc.date.accessioned2012-03-16T16:00:58Z
dc.date.available2012-03-16T16:00:58Z
dc.date.issued2005-05en_US
dc.identifier.citationMalani, Preeti N.; DePestel, Daryl D.; Riddell, James; Bickley, Susan; Klein, Lisa R.; Kauffman, Carol A. (2005). "Experience with Community‐Based Amphotericin B Infusion Therapy." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 25(5). <http://hdl.handle.net/2027.42/90368>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90368
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCommunity‐Based Therapyen_US
dc.subject.otherAdverse Effectsen_US
dc.subject.otherNephrotoxicityen_US
dc.subject.otherMonitoringen_US
dc.subject.otherAmphotericin Ben_US
dc.titleExperience with Community‐Based Amphotericin B Infusion Therapyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Health System.en_US
dc.contributor.affiliationumUniversity of Michigan Home Care Services, University of Michigan Health System.en_US
dc.contributor.affiliationotherVeterans Affairs Healthcare System, Ann Arbor, Michigan.en_US
dc.contributor.affiliationotherDivision of Infectious Diseases, Department of Internal Medicine.en_US
dc.identifier.pmid15899731en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90368/1/phco.25.5.690.63591.pdf
dc.identifier.doi10.1592/phco.25.5.690.63591en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceHarbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528 – 34.en_US
dc.identifier.citedreferenceRehm SJ, Weinstein AJ. Home intravenous antibiotic therapy: a team approach. Ann Intern Med 1983; 99: 388 – 92.en_US
dc.identifier.citedreferenceRehm SJ, Longworth DL. Rates of adverse events associated with community‐based parenteral anti‐infective therapy. J Clin Outcomes Manage 2000; 7: 23 – 8.en_US
dc.identifier.citedreferenceTice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003; 51: 1261 – 8.en_US
dc.identifier.citedreferenceAndrews MM, von Reyn CF Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve endocarditis. Clin Infect Dis 2001; 33: 203 – 9.en_US
dc.identifier.citedreferenceGilbert DN, Dworkin RJ, Raber SR, Leggett JE. Outpatient parenteral antimicrobial drug therapy. N Engl J Med 1997; 337: 829 – 38.en_US
dc.identifier.citedreferenceTice AD, Rehms SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 2004; 38: 1651 – 72.en_US
dc.identifier.citedreferenceHoffman‐Terry ML, Fraimow HS, Fox TR, Swift BG, Wolf JE. Adverse effects of outpatient parenteral antibiotic therapy. Am J Med 1999; 106: 44 – 9.en_US
dc.identifier.citedreferenceChemaly RF, De Parres JB, Rehm SJ, et al. Venous thrombosis associated with peripherally inserted central catheters: a retrospective analysis of the Cleveland Clinic experience. Clin Infect Dis 2002; 34: 1179 – 83.en_US
dc.identifier.citedreferenceKauffman CA. Amphotericin B. Sem Respir Crit Care Med 1997; 18: 281 – 7.en_US
dc.identifier.citedreferenceGallis HA, Drew RA, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308 – 29.en_US
dc.identifier.citedreferenceGoodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755 – 61.en_US
dc.identifier.citedreferenceAscioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7 – 14.en_US
dc.identifier.citedreferenceWingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402 – 7.en_US
dc.identifier.citedreferenceBates DW, Su L, Yu T, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686 – 93.en_US
dc.identifier.citedreferenceLuber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B‐induced nephrotoxicity. J Antimicrob Chemother 1999; 43: 267 – 71.en_US
dc.identifier.citedreferenceWalsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383 – 96.en_US
dc.identifier.citedreferenceWhite MH, Bowden RA, Sandler ES, et al. Randomized, double‐blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296 – 302.en_US
dc.identifier.citedreferenceWalsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764 – 71.en_US
dc.identifier.citedreferenceOstrosky‐Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new “gold” standard. Clin Infect Dis 2003; 37: 415 – 25.en_US
dc.identifier.citedreferenceWingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double‐blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155 – 63.en_US
dc.identifier.citedreferenceBranch RA. Prevention of amphotericin B‐induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988; 148: 2389 – 94.en_US
dc.identifier.citedreferenceHeidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75: 476 – 81.en_US
dc.identifier.citedreferenceMayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002; 186: 379 – 88.en_US
dc.identifier.citedreferenceJohnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630 – 7.en_US
dc.identifier.citedreferenceDeresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445 – 57.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.25.5.690.63591.pdf
Size:
70.79KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.